CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says

MT Newswires Live

Aug 14

CorMedix's (CRMD) last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.

DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.

RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.

RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.

Price: 7.75, Change: -0.39, Percent Change: -4.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2659128386"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659128386\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659128386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659128386","market":"fut","top_or_hot":-1,"title":"CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says","media":"MT Newswires Live","content":"<html><body><p> CorMedix's (CRMD) last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.</p><p>DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.</p><p>RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.</p><p>RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.</p><p>Price: 7.75, Change: -0.39, Percent Change: -4.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-14 23:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CorMedix's (CRMD) last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.</p><p>DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.</p><p>RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.</p><p>RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.</p><p>Price: 7.75, Change: -0.39, Percent Change: -4.77</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659128386","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659128386","pubTimestamp":1786721454,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CorMedix's  last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.Price: 7.75, Change: -0.39, Percent Change: -4.77","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc.","BK4007":"制药"},"translate_title":"加拿大皇家银行表示，CorMedix 的新主要 DefenCath 客户支持 2026 年的产量和耐用性至 2027 年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix's (CRMD) last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.Price: 7.75, Change: -0.39, Percent Change: -4.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}